<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579369</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-ASC-EB-101</org_study_id>
    <nct_id>NCT02579369</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa</brief_title>
  <official_title>A Phase 1/2 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anterogen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anterogen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II open-label study to evaluate the efficacy and safety of ALLO-ASC-DFU in&#xD;
      patients with Dystrophic Epidermolysis Bullosa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells.&#xD;
      Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as&#xD;
      vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can&#xD;
      enhance wound healing and regeneration of new tissue, finally may provide an new option in&#xD;
      treating a Dystrophic Epidermolysis Bullosa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area of re-epithelization</measure>
    <time_frame>Follow up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of a target wound's re-epithelialization</measure>
    <time_frame>Every time of visit for follow up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken to re-epithelization</measure>
    <time_frame>Over 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by clinically measured abnormality of laboratory tests and adverse events</measure>
    <time_frame>Over 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Dystrophic Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Allogeneic mesenchymal stem cells</intervention_name>
    <description>Dressing for Dystrophic Epidermolysis Bullosa wound.</description>
    <arm_group_label>ALLO-ASC-DFU</arm_group_label>
    <other_name>ALLO-ASC-DFU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polyurethene Film</intervention_name>
    <description>Dressing for Dystrophic Epidermolysis Bullosa wound.</description>
    <arm_group_label>Conventional Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age : 10~60&#xD;
&#xD;
          2. Diagnosed with Dystrophic Epidermolysis Bullosa based on immunofluorescence test.&#xD;
&#xD;
          3. Bullous skin lesion sized over 10 cm^2&#xD;
&#xD;
          4. Test negative for Serum Î²-HCG pregnancy test on screening, if the subject is fertile&#xD;
&#xD;
          5. A subject who is willing to follow the protocol and provide a informed consent on&#xD;
             screening, given that the information with respect to the clinical trial is provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A subject with history of epidermoid carcinoma within a year from screening.&#xD;
&#xD;
          2. A subject who requires antibiotics due to bacterial infection on skin.&#xD;
&#xD;
          3. A subject who was dosed with oral steroid, over 0.5mg/kg a day for subjects under 18,&#xD;
             or over 20mg in 2 weeks for subjects over 18, within 30 days prior to screening.&#xD;
&#xD;
          4. A subject treated with radiotherapy or immunosuppressants, within 30 days prior to&#xD;
             screening.&#xD;
&#xD;
          5. A subject treated with steroids locally, within 30 days prior to screening.&#xD;
&#xD;
          6. A subject with 2-times the maximum-standardized value of ALT, AST, ALP, bilirubin,&#xD;
             total protein&#xD;
&#xD;
          7. A subject with 2-times the maximum-standardized value of BUN, Creatinine&#xD;
&#xD;
          8. A subject with Albumin below 2.0 g/dL.&#xD;
&#xD;
          9. A subject with Hemoglobin below 6 g/dL (anemic).&#xD;
&#xD;
         10. A subject with allergic response to bovine derived protein and fibrin glue.&#xD;
&#xD;
         11. A subject administered with biologic agents or cell therapy, within 30 days prior to&#xD;
             screening.&#xD;
&#xD;
         12. A subject administered with stem cell treatment by IV or subcutaneously to the target&#xD;
             wound, prior to the trial&#xD;
&#xD;
         13. A subject who enrolled into another clinical trial, within 30 days prior to screening&#xD;
&#xD;
         14. A subject with serious disease that can affect on clinical trial.&#xD;
&#xD;
         15. A pregnant or breast-feeding subject.&#xD;
&#xD;
         16. A subject with history of drug abuse within 1 year of clinical significance&#xD;
&#xD;
         17. A subject who cannot proceed according to the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su Chan Kim, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severence Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Su Chan Kim, PhD.</last_name>
    <phone>+82 2 2019-3362</phone>
    <email>kimsc@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gangnam Severence Hospital</name>
      <address>
        <city>Gangnam Gu</city>
        <state>Seoul</state>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Chan Kim, PhD.</last_name>
      <phone>+82 2 2019 3362'</phone>
      <email>kimsc@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Suchan Kim, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>January 1, 2017</last_update_submitted>
  <last_update_submitted_qc>January 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epidermolysis Bullosa</keyword>
  <keyword>stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

